The expression levels of CD90, CD29, CD105, and CD166 for the optimal P4 ALL MSCs were 94.85 ± 4.81%, 95.53 ± 2.07%, 96.27 ± 2.94%, and 95.77 ± 1.90%, respectively, which were comparable to those derived from AA patients showing 95.85 ± 1.18%, 93.06 ± 2.37%, 97.71 ± 0.92%, and 97.17 ± 2.05%, respectively, for each of the markers described above. Here, ALCAM is linked to acute lymphoblastic leukemia.